These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39158670)

  • 1. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
    Rubinstein A; Mabudian M; McNeil D; Patel NC; Wasserman RL; Gupta S; Carrasco P; Chen J; Garcia E; Nagy A; Yel L
    J Clin Immunol; 2024 Aug; 44(8):181. PubMed ID: 39158670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases.
    Mach-Tomalska M; Pituch-Noworolska A; Bień E; Malanowska M; Machura E; Pukas-Bochenek A; Chrobak E; Pac M; Pietrucha B; Drygała S; Kamieniak M; Kasprzak J; Heropolitańska-Pliszka E
    Immunotherapy; 2024 Apr; 16(6):391-403. PubMed ID: 38362629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
    Nagy A; Duff K; Bauer A; Okonneh F; Rondon JC; Yel L; Li Z
    J Clin Immunol; 2023 Dec; 44(1):28. PubMed ID: 38129731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort.
    Yalcin Gungoren E; Yorgun Altunbas M; Dikici U; Meric Z; Eser Simsek I; Kiykim A; Can S; Karabiber E; Yakici N; Orhan F; Cokugras H; Aydogan M; Ozdemir O; Bilgic Eltan S; Baris S; Ozen A; Karakoc-Aydiner E
    J Clin Immunol; 2024 Aug; 44(8):169. PubMed ID: 39098942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
    Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
    Front Immunol; 2020; 11():981. PubMed ID: 32670265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
    Wasserman RL; Melamed I; Kobrynski L; Puck J; Gupta S; Doralt J; Sharkhawy M; Engl W; Leibl H; Gelmont D; Yel L
    Immunotherapy; 2016 Oct; 8(10):1175-86. PubMed ID: 27468136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(
    Angelotti F; Capecchi R; Giannini D; Mazzarella O; Rocchi V; Migliorini P
    Clin Exp Med; 2020 Aug; 20(3):387-392. PubMed ID: 32385734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study.
    Ellerbroek PM; Hanitsch LG; Witte T; Lougaris V; Hagen PMV; Paassen PV; Chen J; Fielhauer K; McCoy B; Nagy A; Yel L
    Immunotherapy; 2024; 16(10):679-691. PubMed ID: 38888495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.
    Li Z; Nagy A; Lindner D; Duff K; Garcia E; Ay H; Rondon JC; Yel L
    J Clin Immunol; 2024 Jun; 44(7):148. PubMed ID: 38896141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
    Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
    Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
    J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
    J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.
    Sanford M
    BioDrugs; 2014 Aug; 28(4):411-20. PubMed ID: 24925799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
    Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
    Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
    [No Abstract]   [Full Text] [Related]  

  • 15. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
    Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
    Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
    Fasshauer M; Borte M; Bitzenhofer M; Pausch C; Pittrow D; Park M; Gladiator A; Jandus P
    Adv Ther; 2023 Dec; 40(12):5168-5187. PubMed ID: 37751025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
    Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
    J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
    Wasserman RL
    Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.